ABC Arbitrage SA Invests $2.52 Million in Amedisys, Inc. (NASDAQ:AMED)

ABC Arbitrage SA purchased a new position in shares of Amedisys, Inc. (NASDAQ:AMED) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 27,782 shares of the health services provider’s stock, valued at approximately $2,522,000.

Other institutional investors also recently bought and sold shares of the company. Pacer Advisors Inc. increased its position in Amedisys by 11,621.9% in the 4th quarter. Pacer Advisors Inc. now owns 558,197 shares of the health services provider’s stock valued at $50,679,000 after acquiring an additional 553,435 shares during the period. Polar Asset Management Partners Inc. purchased a new stake in shares of Amedisys during the 3rd quarter worth approximately $28,953,000. Verition Fund Management LLC boosted its stake in shares of Amedisys by 608.1% during the 3rd quarter. Verition Fund Management LLC now owns 114,774 shares of the health services provider’s stock worth $11,077,000 after acquiring an additional 98,565 shares in the last quarter. Westchester Capital Management LLC lifted its stake in Amedisys by 9.5% in the 3rd quarter. Westchester Capital Management LLC now owns 1,118,802 shares of the health services provider’s stock valued at $107,976,000 after buying an additional 97,476 shares in the last quarter. Finally, Calamos Advisors LLC lifted its stake in Amedisys by 22.7% in the 4th quarter. Calamos Advisors LLC now owns 487,444 shares of the health services provider’s stock valued at $44,255,000 after buying an additional 90,097 shares in the last quarter. 94.36% of the stock is owned by hedge funds and other institutional investors.

Amedisys Price Performance

AMED opened at $92.60 on Friday. The company’s 50-day moving average price is $90.11 and its 200 day moving average price is $93.64. Amedisys, Inc. has a fifty-two week low of $82.15 and a fifty-two week high of $98.95. The firm has a market cap of $3.03 billion, a price-to-earnings ratio of 36.75, a price-to-earnings-growth ratio of 1.82 and a beta of 0.73. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05.

Analyst Upgrades and Downgrades

Separately, Stephens reiterated an “equal weight” rating and issued a $101.00 price target on shares of Amedisys in a report on Wednesday. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $100.75.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.